ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
 PMID: 26574015       2016       Antimicrobial agents and chemotherapy
Abstract: As a follow-up, the in vitro characteristics of mutant HIV-1 containing RT-K65R and/or RT-M184V with IN-Q148R or IN-N155H were also evaluated, alone and in combination, for potential interactions.
Abstract: In clinical trials of coformulated elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF), emergent drug resistance predominantly involved the FTC resistance substitution M184V/I in reverse transcriptase (RT), with or without the tenofovir (TFV) resistance substitution K65R, accompanied by a primary EVG resista


  Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan.
 PMID: 26404079       2016       The Journal of antimicrobial chemotherapy
Abstract: Among the seven major integrase mutations (T66I, E92Q, G140S, Y143C/H/R, S147G, Q148H/K/R and N155H), only one strain harbouring the Q148R mutation was detected.


  Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.
 PMID: 26626277       2015       Journal of translational medicine
Abstract: Neither major resistance-associated IN mutations (T66I/A/K, E92Q/G, T97A, Y143HCR, S147G, Q148H/R/K, and N155H) nor silent mutations known to change the genetic barrier were observed.
Conclusion: None of the previously reported major mutations (T66AIK, E92Q, Y143RCH, S147G, Q148HRK and N155H) associated with resistance to INIs were observed in HIV-1C Ethiopian isolates, indicating that


  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
 PMID: 25808007       2015       Retrovirology
Abstract: Integrase substitutions E92Q, Y143C, E92Q + Y143C, and Q148R conferred relatively low levels of resistance to dolutegravir in HIV-2ROD9 (2- to 6-fold), but Q148K, E92Q + N155H, T97A + N155H and
Abstract: In contrast, HIV-1NL4-3 mutants E92Q + N155H, G140S + Q148R, and T97A + Y143C showed 2-fold, 4-fold, and no increase in EC50, respectively, relative to the parental strain.


  [Resistance profile and genetic barrier of dolutegravir].
 PMID: 25858608       2015       Enfermedades infecciosas y microbiologia clinica
Abstract: Dolutegravir displays in vitro activity against mutant HIV-1 harboring any isolated resistance mutations selected during failures to raltegravir or elvitegravir (Y143C/H/, N155H, Q148H/K/R, E92G/Q, T66A/I/K, T97A, E138A/K, G140A/S).


  Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.
 PMID: 25927004       2015       Acta naturae
Introduction: However, investigation of the DTG effect on HIV-1 isolates from patients insensitive to RAL and EVG showed that Q148H/K/R substitutions in the integrase structure lead to some resistance to DTG.
Introduction: Mutations Q148H/R/K lead to RAL- and EVG-resistance in different HIV-1 subtypes.


  Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
 PMID: 25956162       2015       Antiviral research
Abstract: The frequency of the S119X polymorphism together with Q148H/R (n=8, 63%) or N155H (n=12, 83%) was relatively high compared with that of naive group.


  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
 PMID: 26311843       2015       The Journal of antimicrobial chemotherapy
Table: Q148H/R
Table: Q148R
Discussion: As mutations at codon 140 play a key role in restoring the fitness of Q148 mutants, their occurrence can also influence the emergence of Q148H/R/K, thus explaining the reduced prevalence of Q148 mutants observed in non-B subtypes.


  Dolutegravir for the treatment of HIV-2 infection.
 PMID: 25728072       2015       Journal of clinical virology
Abstract: Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1).


  Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
 PMID: 26378179       2015       Journal of virology
Abstract: RAL and EVG showed reduced activity against both viruses and against enzymes containing Q148R, E92Q Y143R, and G140S Q148R.
Abstract: The results show that the G118R and G140S Q148R substitutions decreased Km' and Vmax'/Km' for strand transfer compared to those of the WT.
Abstract: To study this at a biochemical level, purified recombinant SIVmac239 wild-type (WT) and E92Q, T97A, G118R, Y143R, Q148R, N155H, R263K,



Browser Board

 Co-occurred Entities




   Filtrator